More specifically, while c-Fos-transgenic mice develop osteosarcomas in different skeletal locations, which strongly increase in size from 1 to 7 months of age, the tumor area did not increase in Rsk2-deficient c-Fos-transgenic mice [11, 13]. The gene discussed is FOS; the disease is osteosarcoma.